Evidence map›Paper›PMID 38826303›Full record

ArticlebioRxiv : the preprint server for biology2024

Nanobodies against the myelin enzyme CNPase as tools for structural and functional studies.

Sigurbjörn Markusson, Arne Raasakka, Marcel Schröder, Shama Sograte-Idrissi, Amir Mohammad Rahimi, Ommolbanin Asadpour, Henrike Körner, Dmitri Lodygin, Maria A Eichel-Vogel, Risha Chowdhury and 10 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Sigurbjörn MarkussonDepartment of Biomedicine, University of Bergen, Bergen, Norway.
Arne RaasakkaDepartment of Biomedicine, University of Bergen, Bergen, Norway.ORCID 0000-0002-9443-9959
Marcel SchröderDepartment of Biomedicine, University of Bergen, Bergen, Norway.
Shama Sograte-IdrissiCenter for Biostructural Imaging of Neurodegeneration (BIN), University of Göttingen Medical Center, 37075 Göttingen, Germany.
Amir Mohammad RahimiCenter for Biostructural Imaging of Neurodegeneration (BIN), University of Göttingen Medical Center, 37075 Göttingen, Germany.
Ommolbanin AsadpourCenter for Biostructural Imaging of Neurodegeneration (BIN), University of Göttingen Medical Center, 37075 Göttingen, Germany.
Henrike KörnerDepartment for Neuroimmunology and Multiple Sclerosis Research, University of Göttingen Medical Center, 37075 Göttingen, Germany.
Dmitri LodyginDepartment for Neuroimmunology and Multiple Sclerosis Research, University of Göttingen Medical Center, 37075 Göttingen, Germany.
Maria A Eichel-VogelDepartment of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, D-37075 Göttingen, Germany.
Risha ChowdhuryDepartment of Biomedicine, University of Bergen, Bergen, Norway.
Aleksi SutinenFaculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, Finland.
Gopinath MuruganandamVIB-VUB Center for Structural Biology, Vlaams Instituut voor Biotechnologie, Brussels, Belgium.
Manasi IyerNeurosurgery Department, Stanford University School of Medicine, Stanford, CA, USA.
Madeline H CooperNeurosurgery Department, Stanford University School of Medicine, Stanford, CA, USA.
Maya K WeigelNeurosurgery Department, Stanford University School of Medicine, Stanford, CA, USA.
Nicholas AmbielNeurosurgery Department, Stanford University School of Medicine, Stanford, CA, USA.
Hauke B WernerDepartment of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, D-37075 Göttingen, Germany.
J Bradley ZucheroNeurosurgery Department, Stanford University School of Medicine, Stanford, CA, USA.
Felipe OpazoCenter for Biostructural Imaging of Neurodegeneration (BIN), University of Göttingen Medical Center, 37075 Göttingen, Germany.ORCID 0000-0002-4968-9713
Petri KursulaDepartment of Biomedicine, University of Bergen, Bergen, Norway.ORCID 0000-0001-8529-3751

Funding

How Does Actin Disassembly Drive Myelin Wrapping?R01NS119823 · NINDS · STANFORD UNIVERSITY · PI ZUCHERO, JOHN B · 2020 to 2024
$2.1M
New cell biology tools to study myelin development, dynamics, and diseaseR21NS131999 · NINDS · STANFORD UNIVERSITY · PI ZUCHERO, JOHN B · 2023 to 2023
$437k
NINDS NIH HHS R01 NS119823NINDS NIH HHS R21 NS131999
6 · The paper itself

Abstract

2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase) is an abundant constituent of central nervous system non-compact myelin, frequently used as a marker antigen for myelinating cells. The catalytic activity of CNPase, the 3'-hydrolysis of 2',3'-cyclic nucleotides, is well characterised

Identifiers

PMID38826303
PMCPMC11142274

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.